Soy isoflavones augment radiation effect by inhibiting APE1/ref-1 DNA repair activity in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 688-698

  Singh Gupta, Vinita ^a   Joiner, Michael C ^a   Runyan, Lindsay ^a   Yunker, Christopher K ^a   Sarkar, Fazlul H ^a   Miller, Steven ^a   Gadgeel, Shirish M ^a   Konski, Andre A ^a   Hillman, Gilda G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APE1 Ref 1; Lung cancer; Radiation; Soy isoflavones; H2AX

Indexed keywords

HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; METHOXYAMINE; REDOX EFFECTOR FACTOR 1;

ARTICLE; CANCER CELL; CELL GROWTH; CELL SURVIVAL; DNA BINDING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION;

EID: 79953025164     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821034ae     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer JClin 2009;59:225-249.
2. Armstrong JG, Minsky BD. Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. Cancer Treat Rev 1989;16: 247-255. (Pubitemid 20205944)
3. Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. JClin Oncol 2007;25:947-952. (Pubitemid 350002860)
4. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009;93:408-413.
5. Hillman GG, Forman JD, Kucuk O, et al. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res 2001;7: 382-390. (Pubitemid 32183043)
6. Raffoul JJ, Wang Y, Kucuk O, et al. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006;6:107.
7. Raffoul JJ, Banerjee S, Singh-Gupta V, et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007;67:2141-2149. (Pubitemid 46424233)
8. Raffoul JJ, Banerjee S, Che M, et al. Soy isoflavones enhance radio-therapy in a metastatic prostate cancer model. Int J Cancer 2007;120: 2491-2498. (Pubitemid 46642139)
9. Singh-Gupta V, Zhang H, Banerjee S, et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 2009;124:1675-1684.
10. Singh-Gupta V, Zhang H, Yunker CK, et al. Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res 2010;27:1115-1127.
11. Hillman GG, Wang Y, Kucuk O, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004;3:1271-1279. (Pubitemid 39440172)
12. Wang Y, Raffoul JJ, Che M, et al. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 2006;166:73-80. (Pubitemid 44051228)
13. Hillman GG, Wang Y, Che M, et al. Progression ofrenal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 2007;7:4.
14. Raffoul JJ, Sarkar FH, Hillman GG. Radiosensitization of prostate cancer by soy isoflavones. Curr Cancer Drug Targets 2007;7:759-765.
15. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006;89:1121-1134. (Pubitemid 44972063)
16. Giles D, Wei H. Effect of structurally related flavones/isoflavones on hydrogen peroxide production and oxidative DNA damage in phorbol ester-stimulated HL-60 cells. Nutr Cancer 1997;29:77-82. (Pubitemid 27508128)
17. Ahmad IU, Forman JD, Sarkar FH, et al. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer 2010;62:996-1000.
18. Shimazu T, Inoue M, Sasazuki S, et al. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am J Clin Nutr 2010;91: 722-728.
19. Gadgeel SM, Ali S, Philip PA, et al. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009;115:2165-2176.
20. Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47:111-117. (Pubitemid 38590881)
21. MacPhail SH, Banath JP, Yu TY, et al. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol 2003;79:351-358. (Pubitemid 36920536)
22. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-11304. (Pubitemid 46009960)
23. Wykes SM, Piasentin E, Joiner MC, et al. Low-dose hyper-radiosensi-tivity is not caused by a failure to recognize DNA double-strand breaks. Radiat Res 2006;165:516-524.
24. Shridhar R, Estabrook W, Yudelev M, et al. Characteristic 8 keV X rays possess radiobiological properties of higher-LET radiation. Radiat Res 2010;173:290-297.
25. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiother-apy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91. (Pubitemid 9120186)
26. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007;28:375-395. (Pubitemid 47331610)
27. Harada H, Kizaka-Kondoh S, Li G, et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007;26:7508-7516. (Pubitemid 350207705)